New drug targets rare, aggressive skin cancer after chemotherapy fails
NCT ID NCT07655570
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This pilot study tests the drug ivonescimab in people with advanced or metastatic cutaneous angiosarcoma, a rare and aggressive skin cancer. Participants must have already received chemotherapy with paclitaxel or docetaxel. The study aims to see if ivonescimab is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (AK-112)
- What this could lead to
- If effective, ivonescimab could offer a new treatment option for people with advanced cutaneous angiosarcoma who have already tried chemotherapy.
- What could go wrong
- This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.